Ownership
Private
Employees
~10
Stage
Phase 2
Modalities
Small molecule

Nasus Pharma General Information

Demonstrated 5-year stability for FMXIN002 intranasal epinephrine powder. Phase 2 clinical study showed faster and higher epinephrine levels compared to Epipen autoinjector, with 91% of patients reaching clinical threshold within 6 minutes.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Tel Aviv,
Israel

Drug Pipeline

FMXIN002
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Nasus Pharma's pipeline data

Book a demo

Key Partnerships

APTAR (device partnership)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Nasus Pharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Nasus Pharma's complete valuation and funding history, request access »